developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagsGLP-1

#GLP-1

All articles tagged with "GLP-1"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Archive
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

GLP-1 Articles | Developments Today

GLP-1 use among young children with obesity in US remains rare but is rising rapidly

GLP-1 Prescriptions for Young Children Are Still Rare, but the Growth Is Striking

A new national study tracks GLP-1 prescribing in U.S. children under 12 with obesity.
Use among ages 8 to 11 rose sharply from 2019 to 2026, though overall treatment remains uncommon.
Most children receiving the drugs had severe obesity and many had related health conditions.

DE

DT Editorial Team·Sep 4, 2026·via medicalxpress.com

More in Health→

Some hair loss in men is linked to weight loss drug use

Study links GLP-1 activity to higher male-pattern hair loss risk

Researchers used GLP1R genetics as an indicator of GLP-1 agonist activity.
The study found a 7% added hair-loss risk in men predisposed to androgenetic alopecia.
The association remained after adjusting for hypertension, insulin resistance, and lower testosterone.
The findings support a biological link beyond hair shedding caused by rapid weight loss alone.

DE

DT Editorial Team·Sep 3, 2026·via medicalxpress.com

More in Health→

GLP-1s do not cause major psychiatric harm, according to new study

Study Finds No Major Psychiatric Risk From GLP-1 Drugs

A new integrative review found no link between GLP-1 drugs and major psychiatric harm.
The analysis covered five years of mechanistic, clinical, observational and regulatory evidence.
The finding supports continued use of GLP-1 therapies with routine patient monitoring.

DE

DT Editorial Team·Sep 1, 2026·via medicalxpress.com

More in Health→

GLP-1 drugs may hold few benefits beyond physical health, study finds

GLP-1 Study Finds Limited Spillover Beyond Physical Health

Researchers studied adults with diabetes using Medical Expenditure Panel Survey data from 2012 to 2023.
The paper found little evidence that GLP-1 use changed mental health, self-rated health, employment, or marital status.
The findings could affect how insurers and public programs weigh broader claims about the drugs’ social and economic benefits.

DE

DT Editorial Team·Jul 28, 2026·via medicalxpress.com

More in Health→

Distinct brain circuits explain contradictory behaviors of new weight-loss drugs

Brain circuits may explain why opposite obesity drugs both work

Cambridge researchers used mice to explain why opposite GIPR drug strategies can both promote weight loss.
The study found that GIPR stimulation in the brainstem and GIPR blockade in the hypothalamus can produce similar outcomes.
The results may help researchers design more effective obesity drug combinations with GLP-1-based treatments.
The findings clarify mechanism, but the evidence described here is still preclinical rather than human clinical proof.

DE

DT Editorial Team·Jul 24, 2026·via medicalxpress.com

More in Health→

GLP-1 shows promise for patients with advanced fatty liver disease

Semaglutide shows antifibrotic signal in advanced MASH trial

Large Phase 2 trial data suggest semaglutide may reduce fibrosis in advanced MASH.
The benefit was reported without worsening liver inflammation.
Patients with compensated cirrhosis were included, addressing a major unmet-need group.
The semaglutide-zalfermin combination did not beat placebo.

DE

DT Editorial Team·Jul 17, 2026·via medicalxpress.com

More in Health→

$Semaglutide linked to lower bone fracture risk$

Semaglutide study links diabetes treatment to lower fracture risk

ENDO 2026 researchers reported a 15% lower fracture rate with semaglutide.
The study compared semaglutide with dulaglutide and two oral weight-loss therapies.
The analysis used U.S. electronic health records from 2016 through 2023.
Authors say prospective studies are still needed.

DE

DT Editorial Team·Jun 14, 2026·via medicalxpress.com

More in Health→

GLP-1s may alleviate depression through the microbiome, mouse study suggests

GLP-1 Drugs May Ease Depression via Gut Microbiome, Mouse Study Finds

Liraglutide accumulated in the intestine, not the brain, in stressed mice.
Antidepressant effects persisted in mice with GLP-1 receptors knocked out.
Depleting gut microbiota with antibiotics eliminated the antidepressant effect.
Lactobacillus delbrueckii increased significantly and produces a precursor to the endocannabinoid 2-AG.

DE

DT Editorial Team·Jun 10, 2026·via medicalxpress.com

More in Health→

Gilead and Merck's latest trial success and flop

Gilead and Merck's Latest Trial Success and Flop: Biotech Roundup

Gilead and Merck had one successful trial and one failed trial.
AstraZeneca's oral GLP-1 pill showed positive Phase 2b results.
GSK acquired a cancer startup for $10.6 billion.
Other news: Regeneron's Eylea, Bluebird Bio gene therapy approval, FDA rejection.

DE

DT Editorial Team·Jun 10, 2026·via statnews.com

More in Health→

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca's Oral GLP-1 Pill Shows Promise in Mid-Stage Obesity and Diabetes Trials

AstraZeneca's oral GLP-1 pill showed 12% average weight loss in Phase 2 obesity trial.
Diabetes patients achieved significant HbA1c reductions with the once-daily pill.
Safety profile consistent with GLP-1 class; GI side effects mild to moderate.
Analysts say it's too early to compare with Novo Nordisk's Rybelsus or Lilly's orforglipron.

DE

DT Editorial Team·Jun 9, 2026·via statnews.com

More in Health→

Ozempic, GPL-1s may help curb substance use disorders, study finds

GLP-1 Drugs Like Ozempic Linked to Lower Risk of Substance Use Disorders, Study Finds

UTEP study of 142,000 patients found GLP-1 users had 74% lower alcohol use disorder odds, 69% lower opioid, 68% lower nicotine, and 75% lower cocaine use disorder odds.
Researchers caution the observational study does not prove causation; randomized trials are needed before prescribing GLP-1s for addiction.
GLP-1s may affect dopamine signaling and reward pathways, potentially reducing cravings for substances beyond food.

DE

DT Editorial Team·Jun 8, 2026·via medicalxpress.com

More in Health→

Scientists discover why ozempic may not work for some people

Genetic variants may blunt blood-sugar response to GLP-1 drugs

Researchers linked certain variants to weaker glycemic response to GLP-1 drugs.
The study estimates roughly 10% of people carry these variants.
The finding may help move diabetes treatment toward precision medicine.

DE

DT Editorial Team·Jun 6, 2026·via sciencedaily.com

More in Science→

Scientists unlock a way to maintain GLP-1 efficacy long-term

NIH-backed research identifies a brain signaling pathway that could extend and strengthen semaglutide’s weight-loss эфф

Researchers linked semaglutide’s effect to cAMP signaling in area postrema neurons.
Some neurons sustain the response while others quickly lose it, which may help explain plateaus.
A PDE4 inhibitor, roflumilast, appeared to restore signaling in the mouse-model study.

DE

DT Editorial Team·May 28, 2026·via refractor.io

More in Innovation→

Ozempic Is Finally Turning the Tide Against Obesity, New Data Shows

GLP-1 prescribing surge coincides with a modest decline in obesity data

A large health-records dataset shows GLP-1 prescriptions rising more than fourfold since 2021.
The same dataset shows a modest decline in obesity rates over that span.
The data is early but suggests anti-obesity drugs may be shaping outcomes at scale.

DE

DT Editorial Team·May 26, 2026·via gizmodo.com

More in Culture→

Study links use of new obesity drugs to reduction of asthma exacerbations and inhaler use

GLP-1 obesity drugs are linked to fewer asthma flare-ups in new Danish study

The study was presented at the European Congress on Obesity in Istanbul.
Researchers reported a 26% fall in asthma exacerbations after GLP-1 treatment began.
Reliever inhaler use dropped by 14% in the same population.

DE

DT Editorial Team·May 15, 2026·via medicalxpress.com

More in Health→

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine

Oral GLP-1 candidate helps patients hold onto weight loss after injectable therapy

Phase 3b data showed oral orforglipron preserved more prior weight loss than placebo after injectable therapy.
Benefits were seen in participants previously treated with either tirzepatide or semaglutide.
The study supports an oral maintenance strategy but did not compare switching with staying on injectables.

DE

DT Editorial Team·May 13, 2026·via nature.com

More in Health→

European regulators greenlight first clinical test of GLP-1 gene therapy

Europe’s green light for Fractyl’s GLP-1 gene therapy test marks a new front in obesity medicine

European regulators cleared Fractyl Health to begin a clinical test of a GLP-1 gene therapy.
The source describes it as the first clinical test of its kind.
The effort aims at a potential one-and-done alternative to chronic GLP-1 injections or pills.
The move highlights how quickly obesity and metabolic drug development is expanding.

DE

DT Editorial Team·May 11, 2026·via endpoints.news

More in Health→

New “Trojan horse” obesity drug supercharges weight loss in early tests

A ‘Trojan horse’ obesity drug outperforms standard comparators in mice

Researchers linked an incretin compound to lanifibranor in one hybrid molecule.
The treatment improved appetite, weight, and glucose outcomes in mice.
The study remains preclinical and does not yet establish human efficacy or safety.

DE

DT Editorial Team·May 9, 2026·via sciencedaily.com

More in Science→

Medicare Opens a Limited Path to Weight-Loss Drugs, With Plenty of Fine Print

CMS plans a temporary Medicare GLP-1 Bridge pilot from July 1, 2026 through December 31, 2027.
Eligible beneficiaries could access certain weight-loss GLP-1 medicines for about $50 a month.
The program expands access but leaves open major questions about prior authorization and coverage after 2027.

DE

DT Editorial Team·May 9, 2026·via medicalxpress.com

More in Health→

GLP-1 Prescriptions Surge, but Severe Obesity Still Goes Untreated

Researchers analyzed electronic health records from nearly 20 million patients with severe obesity.
GLP-1 prescriptions grew exponentially in the study population.
The study says severe obesity still often goes untreated.
The findings coincide with a decline in bariatric surgery use.

DE

DT Editorial Team·May 5, 2026·via medicalxpress.com

More in Health→

1
2
Next